| Schedule of stockholders equity |
|
|
|
| |
|
At
December
31, 2025
|
|
| Grant date share price |
|
|
$7.11 - $7.26 |
|
| Grant date exercise price |
|
|
$5.64 - $6.17 |
|
| Expected term |
|
|
0.25 years - 0.5 years |
|
| Expected volatility |
|
|
69.5% - 105.3% |
|
| Risk-free rate |
|
|
3.59% - 4.32% |
|
| Expected dividend rate |
|
|
0% |
|
During the offer period, the Company records stock-based compensation pro rata as an expense and a credit to additional paid-in capital.
The Company issued 22,568 and 18,983 common shares on the option exercise dates of December 31, 2025 and June 30, 2025, respectively.
The following table discloses relevant information for the ESPP for the years ended December 31, 2025 and December 31, 2024, respectively.
| Schedule of
stock-based compensation pro rata |
|
|
|
| |
|
For the Year ended
December
31, 2025 |
|
| Cash payment received from employee withholding |
|
$ |
273,462 |
|
| Cash from employee withholdings used to purchase shares under ESPP |
|
|
(254,001 |
) |
| Accrued employee withholdings at December 31, 2025 |
|
$ |
19,461 |
|
| |
|
|
|
| |
|
For the
Year ended
December 31, 2025 |
|
| Cash from employee withholding used to purchase ESPP shares |
|
$ |
254,001 |
|
| Stock based compensation expense |
|
|
130,282 |
|
| Total increase to equity for year ended December 31, 2025 |
|
$ |
384,283 |
|
| |
|
|
|
| |
|
For the
Year ended
December 31, 2024 |
|
| Cash from employee
withholdings used to purchase ESPP shares
|
|
$ |
166,265 |
|
| Stock
based compensation expense |
|
|
82,826 |
|
| Total
increase to equity for year ended December 31, 2024 |
|
$ |
249,091 |
|
|